Esperion to be acquired by ARCHIMED for $3.16/share plus up to $100M in milestones, valuing deal at $1.1B

Esperion Therapeutics will be acquired by ARCHIMED in a deal valued at up to $1.1 billion, with shareholders receiving $3.16 per share in cash plus the right to up to $100 million in contingent milestone payments based on future sales. The upfront cash price represents a 58% premium over Esperion's closing price on April 30, 2026. The acquisition aims to support Esperion’s growth in cardiometabolic therapies, with the transaction expected to close in Q3 2026 after shareholder and regulatory approvals. Post-acquisition, Esperion will become a private company and delist from Nasdaq.